328 results about "Cysteine l" patented technology

The present invention provides a bacterium which has an ability to produce a useful metabolite derived from acetyl-coenzyme A, such as L-glutamic acid, L-glutamine, L-proline, L-arginine, L-leucine, L-cysteine, succinate, and polyhydroxybutyrate, wherein said bacterium is modified so that activities of D-xylulose-5-phosphate phosphoketolase and / or fructose-6-phosphate phosphoketolase are enhanced. The present invention also provides a method for producing the useful metabolite using the bacterium.

The invention provides a nutrient composition for augmenting immune strength or physiological detoxification. The nutrient composition consists of an optimal combination of an effective amount of at least one vitamin antioxidant, at least one mineral antioxidant and a highly saturable amount of at least three high potency antioxidants. The at least one vitamin antioxidant can be vitamin C, bioflavonoid complex, vitamin E, vitamin B6 or beta-carotene and the at least one mineral antioxidant can be zinc or selenium. The at least three high potency antioxidants can be alpha lipoic acid, acetyl L-carnitine, N-acetyl-cysteine, co-enzyme Q10 or glutathione. Also provided is a nutrient composition for augmenting immune strength or physiological detoxification that consists of an optimal combination of an effective amount of at least three vitamin antioxidants, at least two mineral antioxidants and a highly saturable amount of at least three high potency antioxidants. Further provided is a method of stimulating immune system function or a method of augmenting a therapeutic treatment of a disease. The method consists of administering to an individual a nutrient composition of the invention one or more times a day over a period of about 5-7 weeks, the immune system function being stimulated to result in an increase of CD4+ cells of at least about 15% compared to pre-administration levels. A method of stimulating a physiological detoxification function of an individual or a method of augmenting a therapeutic treatment of a disease is also provided. The method consists of administering to an individual a nutrient composition of the invention one or more times a day over a period of about 5-7 weeks, the physiological detoxification function being stimulated to result in a decrease of one or more free radical markers by about 20% compared to pre-administration levels.

O-acetylserine, L-cysteine and sulphurous compounds derived therefrom may be produced using a bacterium belonging to the genus Escherichia which harbors a mutant feedback-resistant serine acetyltransferases in which the amino acid sequence corresponding to positions from 89 to 96 in a wild-type serine acetyltransferase is replaced with any one of the amino acid sequences shown in SEQ ID NOS: 4 to 9, and feedback inhibition by L-cysteine in the bacterium is desensitized.

The present invention provides a controlled-release composition which provides a therapeutically effective plasma concentration of N-acetylcysteine over prolonged period of time. The present invention also includes the use of the controlled-release composition, either alone or in combination with at least one additional active agent, for reduction of vascular inflammation marker and treatment of diseases, conditions, and / or symptoms associated with systemic and / or vascular inflammation in a patient. Furthermore, the present invention provides a process of making granules comprising N-acetylcysteine, or a salt, solvate, prodrug, and / or analog thereof.

The present invention relates to methods for preventing the development of cancer or neurodegenerative diseases by administering N-Acetylcysteine (NAC), melatonin, or a combination thereof. The present invention also relates to methods for diagnosing cancer and / or neurdegenerative disease by detecting or determining the amount of dopamine metabolites, 4-CE, 2-CE, methylation of CE or CE-Q conjugates.

The invention provides a proliferation culture medium and differentiation culture medium for hepatocyte culture and liver organ preparation. The proliferation culture medium and the differentiation medium both take a culture medium for growth of mammalian cells as a basic culture medium, and an agent for supplementing L-glutamine, a pH value modifier for maintaining the pH values of the culture media stable, a primary cell culture antibiotic, a serum substitute, N-acetylcysteine, arbitrary nicotinamide and any one or more of a BMP inhibitor, a Wnt agonist, a growth factor, a Rock signaling pathway inhibitor, a P38 signal path inhibitor, a Notch signal path inhibitor, dexamethasone, BMP7 and a cAMP activator are added into the culture media. By using the culture media for culturing liver cells, functional liver organs can be obtained.

Novel cysteine prodrugs and their use in the treatment of diseases and / or conditions, including but not limited to diseases and / or conditions of the Central Nervous System (CNS), including but not limited to schizophrenia, drug craving, drug addiction, bipolar disorder, anxiety, depression, Parkinson's disease, Alzheimer's disease, cognitive dysfunction, multiple sclerosis, Amyotrophic lateral sclerosis (ALS), ischemic stroke, HIV dementia, and Huntington's disease.

L-cysteine is produced by culturing an Escherichia bacterium having L-cysteine producing ability and containing a gene encoding an O-acetylserine sulphydrylase B or MalY regulatory protein that is modified so that cysteine desulfhydrase activity is reduced or eliminated. The bacterium is cultured in a medium to produce and cause accumulation of L-cysteine in the medium, and collecting L-cysteine from the medium.

Disclosed are a modified FIX (factor IX) polypeptide comprising a leucine, cysteine, aspartic acid, glutamic acid, histidine, lysine, asparagine, glutamine or tyrosine in position 338; pharmaceutical preparations containing said modified FIX polypeptide; a nucleotide sequence coding for the modified FIX polypeptide; and a method for producing the modified FIX polypeptide.

The invention discloses a composite cheese liver flavor attractant and a preparation method of the composite cheese liver flavor attractant. The composite cheese liver flavor attractant comprises the following raw materials in parts by weight: 1-15 parts of natural cream zymolyte, 30-60 parts of fresh pork liver zymolyte, 0.5-3.5 parts of yeast extract, 0.5-4 parts of xylose, 0-2 parts of cysteine hydrochloride, 0-2 parts of vitamin B1, 0-3.5 parts of glutamic acid, 0-30 parts of dextrin and 15-30 parts of water. The composite cheese liver flavor attractant and the preparation method of the composite cheese liver flavor attractant reasonably utilize waste resources, such as animal livers, as alternative products of meat flavor essence or primary liver products in the pet feed and the special animal feed. The composite cheese liver flavor attractant and the preparation method of the composite cheese liver flavor attractant can ensure the intensity of the liver flavor and the meat flavor of the finished product, efficiently reduce the direct usage of the liver, and ensure the body health of pets and carnivores. The cheese flavor and the liver flavor are properly coordinated. The composite cheese liver flavor attractant has the advantages that the composite cheese liver flavor attractant is rich, heavy, natural, lasting and soft in flavor, and favorable in the animal attracting effect, and the composite cheese liver flavor attractant has favorable high temperature resistance. The composite cheese liver flavor attractant meets national edible standards, and the composite cheese liver flavor attractant is safe and reliable when being used as an attractant.

Cysteine amino-acid compound (or its analogues) used in the disruption of microbial biofilms by treatment of prevention of diseases generated by phytopathogenic bacteria attacking plants of agricultural interest represented by an innovative solution within the agriculture sector, where said compound can be used in the pharmacological form, as a drug associated with fertilizer for the combat of bacterial diseases which form microbial biofilms, such as citrus variegated chlorosis (CVC), citric canker’, huanlongbing (HLB) disease or ‘greening’, amongst other, which inventive concept, as such, never before completed, resides in the benefit deriving from the cysteine amino-acid, and all of its analogues, in the inhibitory action and progressive disruption of the microbial biofilm thus liberating the nutritive flux and hydration of the root to the upper part of the plant and the subsequent regression of the disease symptoms, with the added advantage that the cysteine amino-acid compound is non-toxic, guaranteeing healthy production of foods by plants of agricultural interest that are totally healthy, without toxic residues in their composition, as well as when said compound is applied there is risk to the environment due to the rapid absorption, notably within the area in which it is applied, where such predicates of disease combat, with the exception of toxic collateral effects still guarantee that the final crop and harvest will have a higher productivity per hectare.

The invention discloses a creatine kinase isoenzyme detection reagent. The reagent consists of a reagent R1 and a reagent R2 according to the volume ratio of 4 to 1, wherein the reagent R1 consists of an imidazole buffer liquid, glucose, nano particles, N-acetylcysteine, sodium ethylene diamine tetracetate, adenosine diphosphate, cozymase I, ribonucleotide, pyruvate decarboxylase, glucose 6-phosphate dehydrogenase, hexokinase, a goat anti-human CK-M polyclonal antibody and trehalose; the reagent R2 consists of an imidazole buffer liquid, phosphocreatine, sodium dodecyl benzene sulfonate and a preservative. The reagent disclosed by the invention is a creatine kinase isoenzyme detection reagent which is stable, accurate, and high in anti-interference, and has very high clinical application value.

The invention discloses monatomic nano-enzyme as well as a preparation method and application thereof. The monatomic nano-enzyme is prepared by the following steps that doped metal ions, main metal ions and organic monomers are coordinated in a microfluid reaction device to form conjugated supramolecules in a defect state; and the monatomic nano-enzyme is obtained by performing high-temperature pyrolysis on conjugated supramolecules in a defect state in an inert atmosphere. The organic monomer is coordinated to form a non-metal heteroatom doped carrier, metal ions and non-metal heteroatoms interact with each other, a partial reduction reaction occurs, and the metal ions are coated in a porous super-conjugated carbon carrier and exist in a monatomic form. The preparation method provided by the invention is suitable for preparing monatomic bodies of various metals, the preparation method is simple and easy to implement, and the prepared monatomic nano-enzyme has atomic-scale dispersion active sites. Experimental results show that the monatomic nano-enzyme prepared by the method has good peroxidase-like activity, and has a wide application prospect in the field of rapid detection of cysteine, ascorbic acid, glutathione and the like.